The content on this site is intended for healthcare professionals only
Dr van Tienhoven presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the PREOPANC-1 trial.
This was a phase III randomised trial in which patients with resectable pancreatic cancer received 10 weeks of chemoradiotherapy prior to surgery, or immediate surgery alone.
Median overall survival improved from 13.7 months to 17.1, disease recurrence from 7.9 months to 9.9 months, and two year survival rate from 30% to 42%
For more on these results, watch his interview with ecancer, or read news coverage here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
Latest in immunological technologies that can treat, control, and prevent cancer
OncoAlert Round Up for August 4th - 10th, 2023
